Our Pipeline
Indication | discoveryIND enablingPhase 1Phase 2Phase 3 |
|---|---|
Multiple Myeloma & Hematologic Cancers | |
Solid tumors
| |
Autoimmune disease
| |
Novel ADC Payload Platform
|
Our Indication Areas
1. Multiple Myeloma and Hematologic Cancers
2. Solid Tumors
3. Auto-immune Diseases
4. Novel ADC Payload Platform
Due to their extraordinary potency QLI5 compounds have been evaluated as payloads in ADCs
